Market News
Stay updated with the latest market trends, earnings, and economic indicators.
Cipla enters biologics joint venture with Kemwell, expands presence in Middle East
Biologics venture to see initial investment of up to ₹10 crore; Cipla (EU) forms Cipla Middle East Company in Saudi Arabia
Sensex Today | Stock Market Highlights: Nifty ends below 25,200 after sharp sell-off in last 30 minutes led by banks
Sensex Today | Stock Market LIVE Updates: The markets are under immense pressure. The Nifty index is down over 150 points, falling below the 25,300 mark. The Nifty Bank is also down, falling 400 points. The index is now below the 61,000 mark. Maruti Suzuki, Airtel, M&M and Cipla are the biggest losers.
Cipla Share Price Live Updates: Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
Cipla’s Yurpeak gains ground beyond metros as GLP‑1 market accelerates
Strong uptake is visible across Mumbai, Bengaluru, Delhi, Chennai, Hyderabad, Indore and Pune, as well as smaller but fast‑growing centres such as Cannanore, Vijayawada, Aurangabad, Surat, Faizabad and Mangalore—locations where prescriber activation and distribution density are translating into early conversions.
Accumulate Cipla; target of Rs 1400: Prabhudas Lilladher
Prabhudas Lilladher recommended Accumulate rating on Cipla with a target price of Rs 1400 in its research report dated May 14, 2026.
Cipla: Strong pipeline to help US business recovery
Respiratory and peptide pipeline, alongside a recovery in the US business, could drive the next phase of growth
Nifty recovers 200 points from intra-day lows; IT continues outperformance | Closing Bell
Indian equities erased all the intraday losses with Nifty back above 23,500. TCS, Infosys, HCL Tech, Tech Mahindra, Trent are among top gainers on the Nifty, while losers are NTPC, Power Grid Corp, Cipla, Dr Reddy's Labs and L&T. Among sectors IT index up 4%, while auto, metal, Consumer Durables, realty up 0.5% each. However, pharma, healthcare, power, media, energy down 0.5-1%. Nifty Midcap and Smallcap indices down marginally. Catch Lovish Darad in conversation with Market Experts.
Cipla targets $1 billion US run-rate, guides 18.5–20% Ebitda margin for FY27
“We are expecting that we will be crossing a run rate of $1 billion by the end of FY27,” Managing Director and Global CEO Achin Gupta said in a recent media interaction, underscoring confidence in the company’s pipeline-led recovery.
Cipla, Sun Pharma, Dr Reddy's, Glenmark trade lower after Centre tightens cough syrup sales rules
The broader Nifty Pharma index also traded lower, falling 0.47% to 24,220.10.
Cipla stock up 4% to emerge as top Nifty gainer; Citi sees series of near-term positive US triggers
The stock was trading at Rs 1,407, up 4.08 percent.
Taking Stock: Markets extend losses; Nifty slips below 24,200, Sensex declines 852 pts
Biggest Nifty losers were Trent, M&M, Shriram Finance, SBI Life Insurance, Tech Mahindra, while gainers included Dr Reddy's Labs, Cipla, Jio Financial, Adani Enterprises, Apollo Hospitals.
Nifty Pharma jumps nearly 2%; Dr Reddy's, Sun Pharma and Cipla lead gains, dominate Nifty gainers list
Pharma stocks led the gains on benchmark Nifty 50 and the BSE Midcap index on Tuesday. Dr Reddy's, Sun Pharma and Cipla were the top 3 Nifty gainers, amid news reports that the US FDA has asked Indian firms to help address a shortage of ifosfamide injection.